Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCDS
MCID: SPR126
MIFTS: 40

Superior Semicircular Canal Dehiscence (SCDS)

Categories: Bone diseases, Ear diseases, Rare diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Superior Semicircular Canal Dehiscence

About this section

MalaCards integrated aliases for Superior Semicircular Canal Dehiscence:

Name: Superior Semicircular Canal Dehiscence 12 15
Superior Semicircular Canal Dehiscence Syndrome 12 52
Superior Canal Dehiscence Syndrome 52
Third Mobile Window Syndrome 12
Canal Dehiscence Syndrome 12
Superior Canal Dehiscence 12
Superior Canal Syndrome 12
Anemia, Sickle Cell 71
Scds 52

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080193
UMLS 71 C0002895
Sources

Summaries for Superior Semicircular Canal Dehiscence

About this section
NIH Rare Diseases : 52 Superior semicircular canal dehiscence syndrome is a rare balance disorder characterized by auditory and/or vestibular symptoms. These might include dizziness and vertigo triggered by heavy lifting, straining, coughing or loud sounds that change the middle ear or intracranial pressure, fullness in the ear, autophony (an echo or reverberation in the ear when speaking, chewing or swallowing), hearing loss , nystagmus , or oscillopsia (the apparent motion of objects that are stationary). This condition is caused by an opening (dehiscence) in the bone that overlays the superior (uppermost) semicircular canal within the inner ear. While many patients with superior semicircular canal dehiscence syndrome are able to tolerate their symptoms and reduce or avoid triggering stimuli, others can benefit from surgical repair of the dehiscence.

MalaCards based summary : Superior Semicircular Canal Dehiscence, also known as superior semicircular canal dehiscence syndrome, is related to semicircular canal dehiscence syndrome and otosclerosis, and has symptoms including angina pectoris, abdominal pain and edema. An important gene associated with Superior Semicircular Canal Dehiscence is COCH (Cochlin). The drugs Deferasirox and Hydromorphone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells.

Disease Ontology : 12 An inner ear disease characterized by dehiscence in the bone overlying the superior semicircular canal experience with symptoms of pressure or sound-induced vertigo, bone conduction hyperacusis, and pulsatile tinnitus.

Wikipedia : 74 Superior semicircular canal dehiscence syndrome is a set of hearing and balance symptoms, related to a... more...

Sources

Related Diseases for Superior Semicircular Canal Dehiscence

About this section

Diseases related to Superior Semicircular Canal Dehiscence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 semicircular canal dehiscence syndrome 31.9 NTN1 HMX3
2 otosclerosis 30.4 SDSL RTEL1 CRLF1 COCH
3 labyrinthitis 29.7 PATE1 CRLF1 COCH
4 vestibular neuronitis 29.7 SDSL RTEL1 ASPRV1
5 sickle cell disease 12.4
6 schnyder corneal dystrophy 12.1
7 ehlers-danlos syndrome, spondylodysplastic type, 3 11.8
8 sickle cell anemia 11.8
9 cardiac conduction defect 11.6
10 hemoglobinopathy 11.5
11 qt interval, variation in 11.4
12 carnitine deficiency, systemic primary 11.3
13 spondylocostal dysostosis 3, autosomal recessive 11.2
14 subacute cerebellar degeneration 11.2
15 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 11.0
16 pathologic nystagmus 10.8
17 sensorineural hearing loss 10.8
18 hyperacusis 10.7
19 otitis media 10.6
20 cholesteatoma of middle ear 10.5
21 encephalocele 10.5
22 hypertrophic cardiomyopathy 10.4
23 meniere disease 10.4
24 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
25 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 10.4
26 deafness, autosomal dominant 9 10.4
27 ehlers-danlos syndrome 10.4
28 48,xyyy 10.4
29 meningoencephalocele 10.4
30 perilymphatic fistula 10.4
31 syncope 10.3
32 renal oncocytoma 10.3
33 atrial standstill 1 10.3
34 cardiac arrest 10.3
35 acute chest syndrome 10.3
36 hemosiderosis 10.3
37 congestive heart failure 10.3
38 rare hereditary hemochromatosis 10.3
39 osteoporosis 10.2
40 bone mineral density quantitative trait locus 8 10.2
41 bone mineral density quantitative trait locus 15 10.2
42 sleep apnea 10.2
43 fibrous dysplasia 10.2
44 meningocele 10.2
45 allergic hypersensitivity disease 10.2
46 patulous eustachian tube 10.2
47 acoustic neuroma 10.2
48 facial paralysis 10.2
49 neurilemmoma 10.2
50 intracranial hypertension 10.2

Comorbidity relations with Superior Semicircular Canal Dehiscence via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Superior Semicircular Canal Dehiscence:



Diseases related to Superior Semicircular Canal Dehiscence
Sources

Symptoms & Phenotypes for Superior Semicircular Canal Dehiscence

About this section

UMLS symptoms related to Superior Semicircular Canal Dehiscence:


angina pectoris, abdominal pain, edema, chest pain
Sources

Drugs & Therapeutics for Superior Semicircular Canal Dehiscence

About this section

Drugs for Superior Semicircular Canal Dehiscence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
2
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
6
Proguanil Approved Phase 4 500-92-5 4923
7
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
Desogestrel Approved Phase 4 54024-22-5 40973
10
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
11
Deferiprone Approved Phase 4 30652-11-0 2972
12
Propranolol Approved, Investigational Phase 4 525-66-6 4946
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Levetiracetam Approved Phase 4 102767-28-2 441341
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
17
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
18 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
19
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
20
Memantine Approved, Investigational Phase 4 19982-08-2 4054
21
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
22
Topiramate Approved Phase 4 97240-79-4 5284627
23
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
24
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
25
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
26
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
27
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
28
Donepezil Approved Phase 4 120014-06-4 3152
29
Amitriptyline Approved Phase 4 50-48-6 2160
30
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
31
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
32
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
33
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
34
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
37
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
40
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
41
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
42
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
43 Tocotrienol Investigational Phase 4 6829-55-6
44
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
45 Liver Extracts Phase 4
46 Antipyretics Phase 4
47 Renal Agents Phase 4
48 Antiprotozoal Agents Phase 4
49 Antiparasitic Agents Phase 4
50 Folic Acid Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 706)
# Name Status NCT ID Phase Drugs
1 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
2 Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH) Completed NCT02522104 Phase 4 Siklos
3 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
4 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Completed NCT02731157 Phase 4 Rejuvesol
5 Intranasal Fentanyl Versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children Completed NCT03682211 Phase 4 Fentanyl Citrate;Morphine sulphate
6 Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
7 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated. Completed NCT01609192 Phase 4 Hydrea® (hydroxyurea )
8 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4 Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
9 Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises? Recruiting NCT03541980 Phase 4 Acetaminophen;Normal saline
10 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4 Deferiprone;Deferoxamine
11 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Recruiting NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
12 Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle Patients Active, not recruiting NCT03903133 Phase 4 Vitamin E
13 Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea Active, not recruiting NCT02149537 Phase 4 hydroxyurea
14 Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
15 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
16 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
17 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
18 Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study. Not yet recruiting NCT04005209 Phase 4 Ketamine
19 An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants. Terminated NCT00368186 Phase 4
20 A Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease Terminated NCT00252122 Phase 4 Ketamine
21 An Evaluation of the Effectiveness of Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease: a Double-blind, Placebo-controlled Randomised Trial Terminated NCT00880373 Phase 4 Ibuprofen;Placebo;Diamorphine or Morphine
22 Ketorolac Versus Ibuprofen for the Painful Crisis of Sickle Cell Disease - Southwestern Comprehensive Sickle Cell Center Terminated NCT00115336 Phase 4 Intravenous Ketorolac;Ibuprofen
23 Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil Withdrawn NCT00937144 Phase 4 Viagra (Sildenafil);placebo
24 Non-Invasive Assessment of Opioid Analgesia in Children With Sickle Cell Disease Withdrawn NCT00513864 Phase 4 Dextromethorphan;Codeine;Morphine
25 Transfusion Alternatives Pre-Operatively in Sickle Cell Disease Unknown status NCT00512577 Phase 3
26 Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease Unknown status NCT02525107 Phase 3
27 Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease, a Pilot Study Unknown status NCT02801292 Phase 3 Ketamine
28 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
29 Development of a Ready-to-use Nutraceutical Food for Patients With Sickle Cell Disease (SCD): Testing of Vascular Support Components Unknown status NCT01718054 Phase 2, Phase 3 Chloroquine
30 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF VASO-OCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE Completed NCT02187003 Phase 3 Rivipansel
31 MAST - Magnesium for Sickle Cell Acute Crisis in Children Completed NCT00313963 Phase 3 Magnesium Sulfate;Normal Saline
32 A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease Completed NCT03036813 Phase 3 voxelotor
33 Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease Completed NCT00004408 Phase 3 poloxamer 188
34 A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators Completed NCT00235391 Phase 3 Deferasirox
35 Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Completed NCT02449616 Phase 3 MST-188
36 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Completed NCT01737814 Phase 3 Saline;MST-188
37 A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine Completed NCT00918580 Phase 3
38 Stroke Prevention in Sickle Cell Anemia (STOP 1) Completed NCT00000592 Phase 3
39 Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Completed NCT00000585 Phase 3 penicillin
40 N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
41 Ameliorating Attention Problems in Children With SCD Completed NCT01411280 Phase 3 methylphenidate
42 A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease Completed NCT01142219 Phase 3 L-arginine;Placebo
43 A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA Completed NCT01179217 Phase 3 L-glutamine;Placebo
44 Bicentric Study of the Effect of Inhaled Nitric Oxide Compared to Placebo in Acute Chest Syndrome of Adult Sickle Cell Patients Completed NCT00748423 Phase 2, Phase 3 Nitric Oxide;Placebo
45 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis Completed NCT01197417 Phase 2, Phase 3 Intravenous Magnesium Sulfate;Normal Saline Placebo
46 Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease Completed NCT00560261 Phase 3
47 Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Completed NCT00006400 Phase 3 Hydroxyurea;Placebo
48 Stroke Prevention in Sickle Cell Anemia (STOP 2) Completed NCT00006182 Phase 3
49 Choosing Opioid Management for Pain and Analyzing ACS Rates Equally Completed NCT01380197 Phase 3 Morphine;Nubain
50 Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia Completed NCT00399074 Phase 3 sulfadoxine pyrimethamine

Search NIH Clinical Center for Superior Semicircular Canal Dehiscence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Sodium phenylbutyrate
Sources

Genetic Tests for Superior Semicircular Canal Dehiscence

About this section
Sources

Anatomical Context for Superior Semicircular Canal Dehiscence

About this section

MalaCards organs/tissues related to Superior Semicircular Canal Dehiscence:

40
Bone, Bone Marrow, T Cells, Endothelial, Kidney, Liver, Testes
Sources

Publications for Superior Semicircular Canal Dehiscence

About this section

Articles related to Superior Semicircular Canal Dehiscence:

(show top 50) (show all 323)
# Title Authors PMID Year
1
Temporal Bone Anatomy in Superior Semicircular Canal Dehiscence: A Case Control Study on Bone Pneumatization and the Level of Middle Cranial Fossa. 61
31821267 2020
2
Rhythmic Wave Patterns on Ambient Pressure Tympanometry in Patients With Objective Tinnitus-associated Pathologies. 61
31868782 2020
3
A Case Series of Patients With Concurrent Otosclerosis and Superior Semicircular Canal Dehiscence. 61
31688614 2020
4
Superior Semicircular Canal Dehiscence Syndrome. 61
31986544 2020
5
Contribution of Reformatted Multislice Temporal Computed Tomography Images in the Planes of Stenvers and Pöschl to the Diagnosis of Superior Semicircular Canal Dehiscence. 61
31939882 2020
6
Validating the Utility of High Frequency Ocular Vestibular Evoked Myogenic Potential Testing in the Diagnosis of Superior Semicircular Canal Dehiscence. 61
31725592 2019
7
Superior semicircular canal dehiscence presenting with recurrent positional vertigo. 61
31699689 2019
8
Association between superior semicircular canal dehiscence and other dehiscences in temporal bone. 61
31886879 2019
9
Superior semicircular canal dehiscence postoperative outcomes: A case series of 156 repairs. 61
31383473 2019
10
Gauging the effectiveness of canal occlusion surgery: how I do it. 61
31668162 2019
11
Middle fossa approach for spontaneous cerebrospinal fluid fistula and encephaloceles. 61
31335556 2019
12
Pressure Transmission to the Inner Ear by Mastoid Palpation After Transmastoid Surgery for Superior Canal Dehiscence. 61
31469801 2019
13
Outcomes of transmastoid resurfacing for superior canal dehiscence using a cartilage overlay technique. 61
30632156 2019
14
Why and when to refer patients for vestibular evoked myogenic potentials: A critical review. 61
31299589 2019
15
Quality of life outcomes after transmastoid plugging of superior semicircular canal dehiscence. 61
31761408 2019
16
Skull vibration induced nystagmus in patients with superior semicircular canal dehiscence. 61
31029487 2019
17
Systematic Review of Round Window Operations for the Treatment of Superior Semicircular Canal Dehiscence. 61
31418721 2019
18
Can Wideband Tympanometry Be Used as a Screening Test for Superior Semicircular Canal Dehiscence? 61
30458602 2019
19
CT evaluation of normal bone thickness overlying the superior semicircular canal. 61
31103254 2019
20
Surgical treatments for a case of superior canal dehiscence syndrome associated with patulous Eustachian tube. 61
30287116 2019
21
Comparison of Transmastoid and Middle Fossa Approaches for Superior Canal Dehiscence Repair: A Multi-institutional Study. 61
30832543 2019
22
Posterior semicircular canal dehiscence: a diagnostic and surgical conundrum. 61
31270089 2019
23
Age and gender considerations on the symptomology in patients with superior semicircular canal dehiscence: A systematic review and case illustration. 61
31078378 2019
24
Failure to close the gap: Concomitant superior canal dehiscence in otosclerosis patients. 61
31271445 2019
25
Sealing of superior semicircular canal dehiscence is associated with improved balance outcomes postoperatively versus plugging of the canal in middle fossa craniotomy repairs: a case series. 61
31252395 2019
26
Clinical Assessment of Patients with Bilateral Superior Semicircular Canal Dehiscence. 61
30928582 2019
27
The variation of superior semicircular canal bone thickness in relation to age and gender. 61
31035843 2019
28
Repair of Temporal Bone Defects via the Middle Cranial Fossa Approach: Treatment of 2 Pathologies With 1 Operation. 61
29788439 2019
29
A Comparison of Two Recording Montages for Ocular Vestibular Evoked Myogenic Potentials in Patients with Superior Canal Dehiscence Syndrome. 61
30461389 2019
30
Prevalence of Superior Semicircular Canal Dehiscence on High-Resolution CT Imaging in Patients without Vestibular or Auditory Abnormalities. 61
30819770 2019
31
The Prevalence of Superior Semicircular Canal Dehiscence in Patients With Mastoid Encephalocele or Cerebrospinal Fluid Otorrhea. 61
30870362 2019
32
Flat Panel Computed Tomography in the Diagnosis of Superior Semicircular Canal Dehiscence Syndrome. 61
30570605 2019
33
Bilateral Superior Semicircular Canal Dehiscence Associated with Ehlers-Danlos Syndrome: A Report of 2 Cases. 61
30385359 2019
34
Clinical and Physiologic Predictors and Postoperative Outcomes of Near Dehiscence Syndrome. 61
30570606 2019
35
Functional and Objective Audiovestibular Evaluation of Children With Apparent Semicircular Canal Dehiscence-A Case Series in a Pediatric Vestibular Center. 61
31001191 2019
36
Otolith Function Testing. 61
30947185 2019
37
Vestibular evoked myogenic potentials in practice: Methods, pitfalls and clinical applications. 61
30949613 2019
38
Third Window Syndrome: Surgical Management of Cochlea-Facial Nerve Dehiscence. 61
31920911 2019
39
A Cohort Study of Hearing Outcomes Between Middle Fossa Craniotomy and Transmastoid Approach for Surgical Repair of Superior Semicircular Canal Dehiscence Syndrome. 61
30444849 2018
40
Superior semicircular canal dehiscence with concomitant otosclerosis-A literature review and case discussion. 61
30564330 2018
41
[Optimization of delivering minimum Gd-DTPA at the posterior upper point on tympanic medial wall and hT2W-3D-FLAIR sequence for detecting endolymphatic hydrops]. 61
30585006 2018
42
The Gopen-Yang Superior Semicircular Canal Dehiscence Questionnaire: development and validation of a clinical questionnaire to assess subjective symptoms in patients undergoing surgical repair of superior semicircular canal dehiscence. 61
30674366 2018
43
Postoperative MR imaging features after superior semicircular canal plugging in Minor syndrome. 61
30220585 2018
44
Anterior Canal benign paroxysmal positional Vertigo following surgical Management of superior canal dehiscence. 61
30224218 2018
45
Superior Canal Dehiscence Involving the Superior Petrosal Sinus: A Novel Classification Scheme. 61
30199501 2018
46
Semicircular Canal Dehiscence Syndrome and Vestibular Dysfunction Disqualify a Military Student Pilot. 61
30219121 2018
47
Minimally invasive surgery for superior semicircular canal dehiscence: Results of a four fenestration technique in twenty-one adults. 61
29741293 2018
48
Audiometric and cVEMP Thresholds Show Little Correlation With Symptoms in Superior Semicircular Canal Dehiscence Syndrome. 61
30124614 2018
49
Reducing Radiation Dose for High-resolution Flat-panel CT Imaging of Superior Semicircular Canal Dehiscence. 61
30113564 2018
50
Novel Method of Measuring Canal Dehiscence and Evaluation of its Potential as a Predictor of Symptom Outcomes After Middle Fossa Craniotomy. 61
28945893 2018
Sources

Variations for Superior Semicircular Canal Dehiscence

About this section
Sources

Expression for Superior Semicircular Canal Dehiscence

About this section
Search GEO for disease gene expression data for Superior Semicircular Canal Dehiscence.
Sources

Pathways for Superior Semicircular Canal Dehiscence

About this section
Sources

GO Terms for Superior Semicircular Canal Dehiscence

About this section

Biological processes related to Superior Semicircular Canal Dehiscence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inner ear morphogenesis GO:0042472 8.62 NTN1 HMX3
Sources

Sources for Superior Semicircular Canal Dehiscence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....